TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03769090

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol sulfate combination inhalation aerosol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
Description: Budesonide/albuterol sulfate combination inhalation aerosol
Study: NCT03469479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic resection
Description: R0 resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Description: R0 resection
Study: NCT03769090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate metered-dose inhaler 180 μg
Description: Albuterol sulfate inhalation aerosol
Study: NCT02653547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard multisite two weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-frequency multisite two weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
Study: NCT02834247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.
Study: NCT01759108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebamipide
Description: Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
Study: NCT02808130

Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva

Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva

Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva

Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva

Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva

Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
Study: NCT00470574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01229423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
Study: NCT00455507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Two 10 mg KW-6002 tablets orally once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Two 20 mg tablets orally once a day for 12 weeks
Study: NCT01578304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidafenacin
Description: Tablet, 12 weeks twice daily
Study: NCT00455507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets orally once daily for 12 weeks
Study: NCT02424929

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sedation
Description: Propofol anesthesia administered during entire surgery.
Study: NCT02834247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.
Study: NCT02424929

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Original Surgery
Description: No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
Study: NCT02834247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous infusion.
Study: NCT01307462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Given inhaled PO
Study: NCT00636909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: preparative cytoreduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: preparative cytoreduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: immunosuppressive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: immunosuppressive therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: foster engraftment
Study: NCT02563678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy
Study: NCT01307462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Given PO
Study: NCT02563678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Air/Oxygen
Description: Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen
Description: Breathing 100% oxygen at normal, atmospheric pressure
Study: NCT01091389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Thoracoscopic PV isolation
Description: Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Thoracoscopic PV isolation
Description: Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
Study: NCT00988754

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School children and adolescents as health experts
Description: Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
Study: NCT00076687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline injection at Day 1, Week 12, Week 18
Study: NCT04965545

Intervention type: DIETARY_SUPPLEMENT
Intervention: low copper diet
Description: All patients with wilson disease should receive low copper diet
Study: NCT01132547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Given orally
Study: NCT01578304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine
Description: Tablet, 12 weeks once daily
Study: NCT01643122

Intervention type: OTHER
Intervention: No drug
Description: Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).

Intervention type: OTHER
Intervention: No drug
Description: Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
Study: NCT00864188

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no bacterial strains
Description: Glucono-Delta-Lactone acidified milk containing no bacterial strains

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One probiotic strain - Lactobacillus paracasei NCC2461
Description: Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One probiotic strain - Lactobacillus paracasei NCC2461
Description: Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One probiotic strain - Lactobacillus paracasei NCC2461
Description: Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus
Description: Fermented milk containing two standard yogurt bacterial strains.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus
Description: Fermented milk containing two standard yogurt bacterial strains.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus
Description: Fermented milk containing two standard yogurt bacterial strains.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit B2, B3, C and E, Beta Carotene and Oil
Description: Fermented milk containing nutritional supplements
Study: NCT05141968

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplements (2000 IU/day)
Description: The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
Study: NCT01970878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT 003)
Description: GFF MDI administered as two puffs BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001)
Description: GP MDI administered as two puffs BID
Study: NCT01132547

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02225522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid whole genome sequencing (StatSeq)
Description: Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
Study: NCT01970878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005)
Description: FF MDI administered as two puffs BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Description: Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Study: NCT04214093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort.
Study: NCT04323800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti- SARS-CoV-2 Plasma
Description: SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 non-immune Plasma
Description: Normal human plasma collected prior to December 2019
Study: NCT00489554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 3 doses.
Study: NCT01307462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: Given PO
Study: NCT04580095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI algorithm for apical foreshortening in echocardiography
Description: The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
Study: NCT03708666

Intervention type: OTHER
Group type: OTHER
Intervention: Telemonitoring of blood pressure
Description: Blood pressure monitoring at least once a week.
Study: NCT04280185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: HIPEC is a way of intraperitoneal chemotherapy
Study: NCT00483600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: injections of 2.5mg every other day for 4 weeks
Study: NCT03976882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Hetrombopag

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03647267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Vitreolysis (C3F8 injection)
Description: Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: No intervention; sham injection only
Study: NCT02454062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114
Description: TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114
Description: TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
Study: NCT04792684

Intervention type: DIAGNOSTIC_TEST
Intervention: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Description: Evaluate the performance of a preliminary panel of biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Description: Evaluate the performance of a preliminary panel of biomarkers
Study: NCT03874039

Intervention type: DEVICE
Intervention: Gas sensor
Description: The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.

Intervention type: DEVICE
Intervention: Gas sensor
Description: The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.

Intervention type: DEVICE
Intervention: Sweat Sensor
Description: The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.

Intervention type: DEVICE
Intervention: Sweat Sensor
Description: The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
Study: NCT03794674

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention, since this is a validation study
Study: NCT03954613

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study